The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the product information for Pandemrix should be amended to advise prescribers to take into account preliminary results from epidemiological studies on Pandemrix and narcolepsy, and to perform an individual benefit-risk assessment when considering the use of Pandemrix in children and […]
VRM: Vaccine Industry Deception, Propaganda & Media Collusion
By Joel Lord As far back as 2006 no fewer than 4 major pharmaceutical companies had applied for vaccine patents to combat a novel strain of H1N1 virus: GlaxoSmythKline, Novartis, Baxter International & Medimmune: GlaxoSmithKline Patent WO2006100109 A1 / March 21st, 2006 http://www.theoneclickgroup.co.uk/documents/vaccines/WO2006100109A1.pdf Novartis Patent US 20090047353 / November 6th, 2006 http://www.freshpatents.com/-dt20090219ptan20090047353.php?type=description Baxter Patent US […]
HPV vaccine tolerated across three dosing schedules in Vietnam
Neuzil KM. JAMA. 2011;305:1424-1431. The quadrivalent human papillomavirus vaccine was immunogenic and well tolerated on alternative dosing schedules and comparable with the safety profiles of standard vaccine schedules among adolescent girls in Vietnam, according to new findings presented during a Journal of the American Medical Association media briefing. “Most low-resource countries do not have adolescent […]
Duke Human Vaccine Institute signs research agreement to develop pandemic virus vaccines
DURHAM, N.C. – The Duke Human Vaccine Institute today announced a collaboration and strategic agreement with Novartis Vaccines and Diagnostics to enable the rapid development of a vaccine and accelerate preparedness in case of a pandemic virus threat such as pandemic influenza. The team, composed of Duke and Novartis investigators, will utilize resources of the […]
Alternative Gardasil dosing schedules effective
By Nicole Blazek Patients that were administered the three-dose quadrivalent human papillomavirus vaccine (Gardasil, Merck) with longer intervals between each dose had similar immune responses to those administered the vaccine on a standard dosing schedule, new data indicate. “Clinicians can be reassured that if delays occur in administering the second and third doses of this […]
- « Previous Page
- 1
- …
- 36
- 37
- 38
- 39
- 40
- …
- 57
- Next Page »
